The company also signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Food and Drug Administration to advance and qualify its Human Emulation System to meet regulatory evaluation for product testing.

[3] Emulate's Organs-on-Chips technology has been used to recreate the function of a variety of different organs, including the liver, intestine, brain, kidney, and lung.

The system is designed to reduce some of the complexities of working with Organs-on-Chips technology and is built around the Organ-Chip, which recreates the microenvironment of an organ that is found within the body.

Emulate was spun out from the Wyss Institute for Biologically Inspired Engineering at Harvard University, where the technology was initially invented and then extensively developed.

In March 2016, the company raised a Series B round of investment of $28 million from repeat and new investors, including NanoDimension, ALS Finding a Cure, Atel Ventures and Laboratory Corp. of America Holdings.